Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa.
Africa
Markov simulation
direct-acting antivirals (DAAs)
hepatitis C
low-income countries
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
10
03
2020
revised:
09
07
2020
accepted:
13
07
2020
pubmed:
21
7
2020
medline:
22
6
2021
entrez:
21
7
2020
Statut:
ppublish
Résumé
In Sub-Saharan Africa, chronic hepatitis C (CHC) is a major public health issue. We estimated the long-term clinical benefits of treating CHC with sofosbuvir-based regimens in Cameroon, Côte d'Ivoire and Senegal using Markov model combining data from the literature with estimates of direct-acting antiviral (DAAs) effectiveness in West and Central Africa. Disease progression was simulated with and without treatment in fictive cohorts of patients "diagnosed" with CHC in Cameroon (n = 3224), Côte d'Ivoire (n = 9748) and Senegal (n = 6358). Lifetime treatment benefits were assessed using (a) life-years saved (LYS); (b) life-years (LY) avoided in compensated cirrhosis (CC), decompensated cirrhosis (DC) and hepatocellular carcinoma; and (c) comparison of the proportions of patients at each disease stage with and without treatment. Probabilistic and determinist sensitivity analyses were performed to address uncertainty. Sofosbuvir-based treatment would save [mean, 95% confidence intervals] 3.3 (2.5; 5.7) LY per patient in Cameroon, 2.7 (2.1; 4.8) in Côte d'Ivoire and 3.6 (2.8; 6.3) in Senegal. With treatment, approximately 6% (1%) of the patients still alive in each of the study countries would be in the CC (DC) health state 11 (15) years after CHC diagnosis, vs 15% (5%) without treatment. Scenario analysis showed earlier diagnosis and treatment initiation would dramatically improve LYS and morbidity. Sofosbuvir-based treatment could significantly reduce CHC-related mortality and help control CHC-related liver disease progression in West and Central Africa. However, the goal of disease elimination necessitates a substantial decrease in DAAs prices, greater political commitment and increases in both national and external health expenditures.
Sections du résumé
BACKGROUND
In Sub-Saharan Africa, chronic hepatitis C (CHC) is a major public health issue. We estimated the long-term clinical benefits of treating CHC with sofosbuvir-based regimens in Cameroon, Côte d'Ivoire and Senegal using Markov model combining data from the literature with estimates of direct-acting antiviral (DAAs) effectiveness in West and Central Africa.
METHODS
Disease progression was simulated with and without treatment in fictive cohorts of patients "diagnosed" with CHC in Cameroon (n = 3224), Côte d'Ivoire (n = 9748) and Senegal (n = 6358). Lifetime treatment benefits were assessed using (a) life-years saved (LYS); (b) life-years (LY) avoided in compensated cirrhosis (CC), decompensated cirrhosis (DC) and hepatocellular carcinoma; and (c) comparison of the proportions of patients at each disease stage with and without treatment. Probabilistic and determinist sensitivity analyses were performed to address uncertainty.
RESULTS
Sofosbuvir-based treatment would save [mean, 95% confidence intervals] 3.3 (2.5; 5.7) LY per patient in Cameroon, 2.7 (2.1; 4.8) in Côte d'Ivoire and 3.6 (2.8; 6.3) in Senegal. With treatment, approximately 6% (1%) of the patients still alive in each of the study countries would be in the CC (DC) health state 11 (15) years after CHC diagnosis, vs 15% (5%) without treatment. Scenario analysis showed earlier diagnosis and treatment initiation would dramatically improve LYS and morbidity.
CONCLUSION
Sofosbuvir-based treatment could significantly reduce CHC-related mortality and help control CHC-related liver disease progression in West and Central Africa. However, the goal of disease elimination necessitates a substantial decrease in DAAs prices, greater political commitment and increases in both national and external health expenditures.
Substances chimiques
Antiviral Agents
0
Ribavirin
49717AWG6K
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2643-2654Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
WHO. WHO. Global hepatitis report, 2017. WHO. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed February 19, 2020
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176.
Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-S68.
Nahon P, Layese R, Bourcier V, et al, Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology. 2018;155(5):1436-1450.e6.
Lemoine M, Thursz MR. Battlefield against hepatitis B infection and HCC in Africa. J Hepatol. 2017;66(3):645-654.
Akinyemiju T, Abera S, Ahmed M, et al, The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 2017;3(12):1683-1691.
Lawitz E, Mangia A, Wyles D, et al, Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-1887.
Jacobson IM, Gordon SC, Kowdley KV, et al, Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-1877.
Zeuzem S, Dusheiko GM, Salupere R, et al, Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993-2001.
Afdhal N, Zeuzem S, Kwo P, et al, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
Kowdley KV, Gordon SC, Reddy KR, et al, Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-1888.
WHO. WHO. Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection. 2016:138. http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/. Accessed August 14, 2018
WHO. WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. WHO. http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/. Accessed August 24, 2018
Lacombe K, Moh R, Chazallon C, et al, Treatment of chronic hepatitis C GT1,2,4 in Africa: final results of ANRS TAC trial. CROI, Boston, Massachusetts. Presented at the: CROI2018; 2018; Boston, MA. http://www.croiconference.org/sessions/treatment-chronic-hepatitis-c-gt124-africa-final-results-anrs-tac-trial. Accessed July 6, 2019
Gupta N, Mbituyumuremyi A, Kabahizi J, et al, Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. Lancet Gastroenterol Hepatol. 2019;4(2):119-126.
Agence Nationale de la Statistique et de la Démographie. La population du Sénégal en 2017. http://www.ansd.sn/ressources/publications/Rapport_population_2017_05042018.pdf. Accessed February 19, 2020
Institut National de la Statistique du Cameroun. Recensement Général de la Population et de l'Habitat (RGPH). http://www.statistics-cameroon.org/downloads/La_population_du_Cameroun_2010.pdf. Accessed June 21, 2019
Central Intelligence Agency. The world factbook-age structure. https://www.cia.gov/library/publications/the-world-factbook/fields/2010.htm. Accessed August 14, 2018
Chhatwal J, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics. 2016;34(6):551-567.
El-Kamary SS, Mohamed MM, El-Raziky M, et al, Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int Off J Int Assoc Study Liver. 2013;33(7):982-990.
Gray A, Clarke P, Wolstenholme J, Wordsworth S. Applied Methods of Cost-Effectiveness Analysis in Healthcare. Oxford, UK: Oxford University Press; 2011.
Kutala B, Darrigrand NB, Corinne C, Pierre B, Asselah T, Marcellin P. The impact of direct antiviral agent therapy on liver fibrosis in patient with advanced fibrosis related chronic hepatitis C. J Hepatol. 2018;68:S541.
Pietsch V, Deterding K, Attia D, et al, Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals. J Hepatol. 2018;68:S532-S533.
Chan HLY, Chen CJ, Omede O, et al, The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: volume 4. J Viral Hepat. 2017;24(Suppl 2):25-43.
Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatoloy. 2008;48(2):418-431.
Dienstag JL, Ghany MG, Morgan TR, et al, A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54(2):396-405.
Planas R, Ballesté B, Antonio Álvarez M, et al, Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40(5):823-830.
Yang JD, Mohamed EA, Aziz AOA, et al, Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2(2):103-111.
WHO. Global Health Observatory data repository, life table by country. WHO. http://apps.who.int/gho/data/node.main.LIFECOUNTRY?lang=en. Accessed February 19, 2019
Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;62(6):683-694.
Briggs AH, Weinstein MC, Fenwick EAL, et al, Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Mak Int J Soc Med Decis Mak. 2012;32(5):722-732.
Pol S, Bourliere M, Lucier S, et al, Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol. 2017;66(1):39-47.
Spedicato GA. Markovchain: Easy handling discrete time Markov chains; 2019. https://CRAN.R-project.org/package=markovchain. Accessed July 4, 2019
Tang H, Wu J, Wu B, Xu X, Ye X, Zhang W. Long-term outcomes associated with sofosbuvir-based regimens for treatment of chronic hepatitis C in China. Value Health. 2018;21:S65.
Obach D, Deuffic-Burban S, Esmat G, et al, Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;58(8):1064-1071.
Duchesne L, Lacombe K. Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings. J Viral Hepat. 2018;25(2):108-117.
Boyd A, Duchesne L, Lacombe K. Research gaps in viral hepatitis. J Int AIDS Soc. 2018;21(Suppl 2):e25054.
Duchesne L, Njouom R, Lissock F, et al, HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study. J Int AIDS Soc. 2017;20(1):21446.
Assefa Y, Hill PS, Ulikpan A, Williams OD. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness? Glob Health. 2017;13(1):73.
Chabrol F, Noah Noah D, Tchoumi EP, et al, Screening, diagnosis and care cascade for viral hepatitis B and C in Yaoundé, Cameroon: a qualitative study of patients and health providers coping with uncertainty and unbearable costs. BMJ Open. 2019;9(3):e025415.
Médecins Sans Frontières. Hepatitis C-not even close. Médecins Sans Frontières Access Campaign. https://msfaccess.org/hepatitis-c-not-even-close. Accessed June 21, 2019.
Boyer S, Baudoin M, Nishimwe M, et al, Cost-effectiveness of Sofosbuvir-Based Hepatitis C regimens in Central and West Africa (ANRS 12342). Presented at the: EASL Conference; April 11, 2018; Paris, France.
WHO. WHO. Global health expenditure database 2018 update. WHO. http://www.who.int/health_financing/topics/resource-tracking/ghed-update/en/. Accessed January 16, 2020.
WHO. WHO. The Abuja declaration: ten years on. WHO. http://www.who.int/healthsystems/publications/abuja_declaration/en/. Accessed January 16, 2020.
Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393(10178):1319-1329.
Luhnen M, Waffenschmidt S, Gerber-Grote A, Hanke G. Health economic evaluations of sofosbuvir for treatment of chronic hepatitis C: a systematic review. Appl Health Econ Health Policy. 2016;14(5):527-543.
United Nations. World population prospects. https://population.un.org/wpp/. Accessed April 29, 2019.